SCHEMBL3010506

SCHEMBL3010506

O=S(=O)(c1ccc(F)cc1)C1CCN(c2nc(-c3cc(F)cc(F)c3)cs2)CC1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 9/20 0.57
L3MBTL1 Q9Y468 5/20 0.57
ALDH1A1 P00352 5/20 0.57
NPC1 O15118 5/20 0.54
RAB9A P51151 5/20 0.54
MAPK1 P28482 4/20 0.53
AR P10275 2/20 0.50
MAPT P10636 5/20 0.49
USP2 O75604 1/20 0.49
RECQL P46063 1/20 0.49
HSD17B10 Q99714 1/20 0.49
CYP1A2 P05177 3/20 0.47
CYP2C9 P11712 3/20 0.47
CYP2C19 P33261 3/20 0.47
CYP3A4 P08684 2/20 0.47
LMNA P02545 4/20 0.45
KMT2A Q03164 2/20 0.45
MEN1 O00255 1/20 0.45
GAA P10253 1/20 0.45
HTT P42858 4/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3010362 0.93 SMN1; SMN2 (0.53) SMN1; SMN2L3MBTL1ALDH1A1NPC1RAB9A
SCHEMBL3016086 0.93 SMN1; SMN2 (0.51) SMN1; SMN2L3MBTL1ALDH1A1NPC1RAB9A
SCHEMBL3017457 0.93 SMN1; SMN2 (0.51) SMN1; SMN2L3MBTL1ALDH1A1NPC1RAB9A
SCHEMBL3012288 0.93 SMN1; SMN2 (0.49) SMN1; SMN2L3MBTL1ALDH1A1NPC1RAB9A
SCHEMBL3003079 0.91 SMN1; SMN2 (0.55) SMN1; SMN2L3MBTL1ALDH1A1NPC1RAB9A
SCHEMBL3016724 0.90 SMN1; SMN2 (0.54) SMN1; SMN2L3MBTL1ALDH1A1NPC1RAB9A
SCHEMBL3011075 0.90 MAPT (0.54) SMN1; SMN2L3MBTL1ALDH1A1NPC1RAB9A
SCHEMBL3015937 0.90 SMN1; SMN2 (0.47) SMN1; SMN2L3MBTL1ALDH1A1NPC1RAB9A
SCHEMBL3019905 0.90 NPC1 (0.54) SMN1; SMN2L3MBTL1ALDH1A1NPC1RAB9A
SCHEMBL3012097 0.90 SMN1; SMN2 (0.47) SMN1; SMN2L3MBTL1ALDH1A1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA SMN1; SMN2 1/4885L3MBTL1 1847/4885ALDH1A1 3510/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.